TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04091841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: protein supplement
Description: Three sachet of protein supplement to be mixed in with water used daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Carbo Mass
Description: Three sachet of Carbo Mass supplement to be mixed in with water used daily.
Study: NCT02741947

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa Benserazide Madopar
Description: Madopar 100+25mg and 200+50mg, tablet, tid e qid, for four weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa Benserazide Teva Italia
Description: Levodopa benserazide Teva 100+25mg and 200+50mg, tablet, tid e qid, for four weeks
Study: NCT00917592

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin plus clavulanic acid
Description: intravenous amoxicillin plus clavulanic acid 1 gr every 8 hours 48 hours followed by oral amoxicillin plus clavulanic acid 1 gr every 8 hours for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin plus clavulanic acid
Description: intravenous amoxicillin plus clavulanic acid 1 gr every 8 hours 48 hours followed by oral amoxicillin plus clavulanic acid 1 gr every 8 hours for 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin plus clavulanic acid
Description: intravenous amoxicillin plus clavulanic acid for 7 days followed by oral antibiotic for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin plus clavulanic acid
Description: intravenous amoxicillin plus clavulanic acid for 7 days followed by oral antibiotic for 5 days
Study: NCT04420806

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HIT-exercise
Description: 13 months of high intensity endurance and resistance exercise, 3x 45 min/week - 3 months of COVID-19 induced exercise break
Study: NCT03902327

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NAC group
Description: Nutrition intervention focused on the treatment of carbohydrate metabolism disorder + N - acetylocysteine supplementation (1600 mg /d, 400 mg x 4 times a day)(30 people).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Nutrition intervention focused on the treatment of carbohydrate metabolism disorder + placebo (4 times a day) (30 people).
Study: NCT04176549

Intervention type: OTHER
Intervention: Management of Ectopic Pregnancy
Description: Expectant, Medical or Surgical management of Ectopic Pregnancy

Intervention type: OTHER
Intervention: Management of termination of pregnancy
Description: Surgical termination of pregnancy
Study: NCT04420806

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham intervention
Description: Types of exercise (flexibility, relaxation) that did not affect the present outcomes
Study: NCT02575664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: Buprenorphine 5 microg/h/7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo patch
Study: NCT02719405

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus GG
Description: Lactobacillus GG

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Extensively Hydrolyzed Casein Formula
Description: Extensively Hydrolyzed Casein Formula

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Extensively Hydrolyzed Casein Formula
Description: Extensively Hydrolyzed Casein Formula
Study: NCT04176549

Intervention type: OTHER
Intervention: Elective management of gynaecology patients
Description: Elective hysterectomy and salpingo-oophorectomy
Study: NCT02639234

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vigil™
Description: Upon completion of nivolumab infusion, subjects will receive Vigil™, 1.0 x 10\^7cells via intradermal injection on Day 1 every 14 days for a minimum of 4 and a maximum of 12 doses depending on quantity of Vigil™ manufactured from surgical specimens.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Prior to Vigil™, subjects will receive nivolumab 3 mg/kg by intravenous infusion over 60 minutes on Day 1 every 14 days. If nivolumab is administered beyond 12 months it will be administered off study.
Study: NCT03167645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human albumin
Description: Substitution according to pre-specified dosage
Study: NCT03490747

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity referral scheme
Description: An 18-week physical activity referral scheme co-developed by a local multidisciplinary stakeholder group. Behaviour change support underpinned by Self-Determination Theory (Ryan \& Deci, 2000) will be provided by an exercise referral practitioner at weeks 1,4,8,12 and 18 to facilitate increased physical activity levels. Patients will be supported to develop a tailored programme of physical activity that may involve use of the fitness centre facilities (e.g. swimming, group classes, gymnasium use), participation in community-based initiatives, and changes to habitual physical activity. Focus on promoting patient autonomy and tailoring activities to patient's preferences and needs. Subsidised access to fitness centre facilities for first 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care exercise referral scheme
Description: A comparative usual care exercise referral scheme that includes fitness centre based activities (e.g. swimming, group classes, gymnasium use). Patients meet an exercise referral practitioner at their induction (week 1) and week 12 (post scheme). Patients are typically prescribed a gym-based, 12-week programme. Subsidised access to fitness centre facilities for 12 weeks.
Study: NCT01837199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole plus Amoxicillin
Description: All subjects will receive scaling and root planing combined with systemic metronidazole (400 mg) and amoxicillin (500 mg). Both antibiotics were administered T.I.D. for 14 days.
Study: NCT04404530

Intervention type: DRUG
Intervention: Palynziq
Description: Participants will take Palynziq as prescribed by their genetics doctor. In accordance with the Palynziq Risk Evaluation and Mitigation Strategy (REMS) protocol, patients will have their first injection of Palynziq at the Emory Genetics Clinic under the supervision of a physician. After initiating therapy, patients will continue to mail in blood spot filter papers and 3-day dietary records to their clinic providers as standard components of clinical care.
Study: NCT02719405

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Amino Acid Formula
Description: Amino Acid Formula
Study: NCT02259608

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG vaccine SSI
Description: BCG vaccination
Study: NCT03081195

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MFG
Description: The MFG is a series of weekly meetings guided by a protocol.Over the course of 16 weeks, groups are held weekly and are facilitated by trained and supervised group leaders (in this case either parent peers or community health outreach workers). Groups can consist of up to 20 families involving adult caregivers and all children over six years of age in the family. The protocols have been designed to provide opportunities during each session to directly apply content to the realities of family life, emergent cultural and values perspectives, as well as tailor messages to age of child. Redundancy for missed appointments and opportunities for reinforcement is built in. We aim for families to attend at least 8 meetings or more (out of 16 sessions in total), as findings suggests this dose is needed to reduce child conduct problems and the majority of families reach this goal.
Study: NCT01358526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone/Naloxone Controlled-release
Description: Oxycodone/Naloxone Controlled-release tablets (10/5 mg, 20/10 mg, 30/15 mg, 40/20 mg) taken orally every 12 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets to match OXN taken orally every 12 hours
Study: NCT05804058

Intervention type: PROCEDURE
Intervention: Revision surgery
Description: Patients due to undergo prosthetic revision surgery for any reason (infection or aseptic)
Study: NCT01235455

Intervention type: DRUG
Intervention: Interferon beta-1b (Betaseron, BAY86-5046)
Description: 250 µg, sub-cutaneously, on alternate days
Study: NCT02720484

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT03841643

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: patient-specific implant
Description: solid titanium implant that functions as a guiding template for harvesting, and as an implant for reconstruction of the cranial defect

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cement
Description: norian cement for reconstruction of the cranial defect
Study: NCT01859455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGT209 50 mg
Description: Active experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGT209 300 mg
Description: Active experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGT209 300 mg
Description: Active experimental drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statins (atorvastatin or simvastatin)
Description: Stable doses of atorvastatin or simvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statins (atorvastatin or simvastatin)
Description: Stable doses of atorvastatin or simvastatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Statins (atorvastatin or simvastatin)
Description: Stable doses of atorvastatin or simvastatin
Study: NCT03666676

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Signal processing to improve intelligibility
Description: Signal processing will be used to manipulate frequency and amplitude fluctuations in complex sounds.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Signal processing to improve intelligibility
Description: Signal processing will be used to manipulate frequency and amplitude fluctuations in complex sounds.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Signal processing to improve intelligibility
Description: Signal processing will be used to manipulate frequency and amplitude fluctuations in complex sounds.
Study: NCT02520245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN2810
Description: Patients will receive REGN2810 by intravenous (IV) infusion
Study: NCT02439346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1143269 tablet
Description: BAY 1143269 5 mg or 25 mg tablet. Each treatment cycle will last 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1143269 tablet
Description: BAY 1143269 5 mg or 25 mg tablet. Each treatment cycle will last 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1143269 tablet
Description: BAY 1143269 5 mg or 25 mg tablet. Each treatment cycle will last 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1143269 tablet
Description: BAY 1143269 5 mg or 25 mg tablet. Each treatment cycle will last 21 days.
Study: NCT02939222

Intervention type: DEVICE
Group type: OTHER
Intervention: Implant placement
Description: Routine implant placement in the ideal three dimensional implant position
Study: NCT03556319

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2-HOBA
Description: 2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2-HOBA
Description: 2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study: NCT01273272

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive, CBT-based, multi-component treatment
Description: It includes eight modules: diagnosis and goal setting; psychoeducation; engagement in pleasant activities; cognitive restructuring; live review; training caregiver in behavior man-agement techniques; interventions for the caregiver; and couples counselling. It consists of 20 weekly sessions (plus appr. 5 single session with caregiver).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Each patient/caregiver must receive at least three out of six interventions: (1) psychoeducation on dementia and treatment of dementia (oral and written); (2) appropriate medical treatment; (3) social counseling by specialized staff; (4) memory training in group setting; (5) self-help group for the patient; (6) self-help group for the caregiver.
Study: NCT03872050

Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention apart from tests, including interview
Description: No interventions
Study: NCT01962974

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab 2 mg/kg IV
Description: Study drug (golimumab 2 mg/kg IV) will be administered as an intravenous (IV) infusion at Weeks 0, 4, 12, 20 and 28.
Study: NCT01390558

Intervention type: PROCEDURE
Intervention: custom orthotics
Description: Orthotics are fabricated uniquely for each patient and use molds or casts of their foot as the template. They are fabricated by a licensed orthotist. There is no device or brand name other than custom orthotics.
Study: NCT04463901

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pterygium excision
Description: Partial conjunctiva and anterior tenon's membrane underneath will be removed after the excision of pterygium tissue.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pterygium excision
Description: Partial conjunctiva and anterior tenon's membrane underneath will be removed after the excision of pterygium tissue.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative mitomycin C
Description: Intraoperative mitomycin C (0.02%) will be applied for 5 minutes after pterygium excision.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative mitomycin C
Description: Intraoperative mitomycin C (0.02%) will be applied for 5 minutes after pterygium excision.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conjunctival autograft
Description: A conjunctival autograft will be applied to cover the conjunctival defect after pterygium excision.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Limbal conjunctival autograft
Description: A limbal conjunctival autograft will be applied to cover the conjunctival defect after pterygium excision.
Study: NCT04397081

Intervention type: OTHER
Intervention: HPV test results
Description: The human papillomavirus (HPV) test detects the presence of the human papillomavirus, a virus that can lead to the development of genital warts, abnormal cervical cells or cervical cancer. The procedure includes taking samples of your cervical cells using a soft brush and a flat scraping device called a spatula. This doesn't hurt, and you may not even feel the sample being taken.

Intervention type: OTHER
Intervention: HPV test results
Description: The human papillomavirus (HPV) test detects the presence of the human papillomavirus, a virus that can lead to the development of genital warts, abnormal cervical cells or cervical cancer. The procedure includes taking samples of your cervical cells using a soft brush and a flat scraping device called a spatula. This doesn't hurt, and you may not even feel the sample being taken.
Study: NCT01455649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Group will switch calcineurin inhibitor to everolimus within 1 day (overnight).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calcineurin inhibitor
Description: Group will maintain their initial immunosuppression therapy with calcineurin inhibitor
Study: NCT02006030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-PEG 20

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transarterial chemoembolization
Study: NCT04173533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral azacitidine
Description: Oral azacitidine (CC-486) 200 mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched placebo
Description: Oral azacitidine (CC-486) matched placebo tablet
Study: NCT04471259

Intervention type: OTHER
Intervention: Classification statistics
Description: We classified patients by gender, age, recovery time,etc

Intervention type: OTHER
Intervention: Classification statistics
Description: We classified patients by gender, age, recovery time,etc
Study: NCT01732055

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Partner-Assisted Interpersonal Psychotherapy
Study: NCT04158401

Intervention type: DEVICE
Intervention: Pregnolia
Description: The Pregnolia measurement device (CE Mark for commercialization in the EU) will be used to measure the cervical stiffness (Pcl) on all subjects.

Intervention type: DEVICE
Intervention: Pregnolia
Description: The Pregnolia measurement device (CE Mark for commercialization in the EU) will be used to measure the cervical stiffness (Pcl) on all subjects.

Intervention type: DEVICE
Intervention: Pregnolia
Description: The Pregnolia measurement device (CE Mark for commercialization in the EU) will be used to measure the cervical stiffness (Pcl) on all subjects.

Intervention type: DEVICE
Intervention: Pregnolia
Description: The Pregnolia measurement device (CE Mark for commercialization in the EU) will be used to measure the cervical stiffness (Pcl) on all subjects.
Study: NCT00955877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-release Epidural morphine (EREM) 80
Description: After completion of the rhizotomy, the dura will be closed in the standard water-tight fashion with running suture. Epidural DepoDur (80μg/kg) will be placed under direct vision in the L1 laminectomy defect. It will also be dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-release Epidural Morphine (EREM) 120
Description: After completion of the rhizotomy, the dura will be closed in the standard water-tight fashion with running suture. Epidural DepoDur (120μg/kg) will be placed under direct vision in the L1 laminectomy defect. It will also be dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control: Saline
Description: After completion of the rhizotomy, the dura will be closed in the standard water-tight fashion with running suture. Preservative-free normal saline (2.5 ml) will be placed under direct vision in the L1 laminectomy defect. It will also be dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter.
Study: NCT02212223

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Study: NCT04297878

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic supplement Streptococcus salivarius K12 (Bactoblis®)
Description: Probiotic food supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotic supplement Streptococcus salivarius K12 (Bactoblis®)
Description: Probiotic food supplement
Study: NCT01920295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoballoon ablation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoballoon ablation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation
Study: NCT04159831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTI-01
Description: single-chain urokinase plasminogen activator, scuPA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTI-01
Description: single-chain urokinase plasminogen activator, scuPA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTI-01
Description: single-chain urokinase plasminogen activator, scuPA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normal saline
Study: NCT01732055

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: Because treatment(s) are prescribed for subjects by the UNC Perinatal Psychiatry physicians, it is impossible for the investigators to list each potential medication and dosage that might be prescribed to women randomized to this condition. The medication regimens are individual, and some women may opt against medication altogether (and still be eligible to enroll). Women who refuse antidepressant medication will attend visits at the same intervals as those in the study arms for evaluation of safety and symptoms.
Study: NCT02769143

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-Body Vibration
Description: Will be performed six months of WBV exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Description: Will be performed six months of Pilates exercises
Study: NCT03357042

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise and balance retraining
Description: Aerobic and balance exercises that gradually progress in intensity over the course of 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Normal concussion treatment; physical and cognitive rest

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Normal concussion treatment; physical and cognitive rest
Study: NCT02746692

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fit15
Description: Group-based high-intensity circuit training based on functional movement patterns (e.g. squats, push-ups, burpees, jumps, ropeskipping).~Total duration 15 minutes circle training: 20s workout, 10 rest

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endurance
Description: Moderate intensity ergometer training. Total duration 50 minutes